Relay Therapeutics, Inc. RLAY
18.60 USD +1.60 (+9.41%)
At closeNov 6, 2026, 5:45 PM EST
18.88 +0.28 +1.51%
After hours · Nov 6, 5:45 PM ET
16.66 Day range 18.72
6.05 52-week range 20.75
- YTD
- +119.86%
- 1 year
- +184.84%
Financial health
Altman Z-Score
23.54 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
2 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
Rating
C2 / 5 overall
- DCF 1
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 4
- P/E 1
- P/B 2
Valuation
P/E -5.3×
FY 2018 5y median -5.3× FY 2025
P/S 94.5×
FY 2018 5y median 94.5× FY 2025
P/B 2.6×
FY 2018 5y median 1.8× FY 2025
P/FCF -6.2×
FY 2018 5y median -6.2× FY 2025
EV/EBITDA -5.1×
FY 2018 5y median -5.1× FY 2025
EV/Sales 91.2×
FY 2018 5y median 91.2× FY 2025
FCF Yield -16.2%
FY 2018 5y median -16.2% FY 2025
Profitability
Gross Margin 76.8%
FY 2018 5y median -3052.2% FY 2025
Operating Margin -1971.6%
FY 2018 5y median -3722.1% FY 2025
Net Margin -1800.6%
FY 2018 5y median -3374.7% FY 2025
ROE -48.8%
FY 2018 5y median -43.4% FY 2025
ROIC -50.5%
FY 2018 5y median -45.1% FY 2025
ROA -44.5%
FY 2018 5y median -38.8% FY 2025
Growth (YoY)
Revenue 53.4%
FY 2018 FY 2025
Operating Income 18.7%
FY 2018 FY 2025
EPS (diluted) 31.8%
FY 2018 FY 2025
Free Cash Flow 6.1%
FY 2018 FY 2025
Financial Health
Current Ratio 22.6×
FY 2018 5y median 22.6× FY 2025
Quick Ratio 22.6×
FY 2018 5y median 22.6× FY 2025
Debt / Equity 0.1×
FY 2018 5y median 0.1× FY 2025
Net Debt / EBITDA 0.2×
FY 2018 5y median 0.2× FY 2025
Interest Coverage 0.0×
FY 2018 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2018 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2018 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31
